According to filings with the U.S. Securities and Exchange Commission, Rejuvenate Bio is raising $6,000,000.00 in new Crowdfunding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: VCapital, Merck Animal Health, Kendall Capital Partners, Connecticut Innovations, Digitalis.

About Rejuvenate Bio
Rejuvenate Bio is a biotechnology company developing gene therapy approaches to treat chronic, age-related diseases by targeting the root causes of aging. The company focuses on creating life-changing treatments for serious chronic conditions rather than just managing symptoms, aiming to extend healthy years of life. Its platform is built around precise genetic interventions designed to modify biological pathways that drive aging and age-related decline. Positioned at the intersection of aging research and advanced gene therapy, Rejuvenate Bio presents itself as an innovator working to translate cutting-edge science into practical therapies for patients. Through this strategy, the company seeks to address a broad range of age-linked diseases with durable, one-time treatments that have transformative clinical impact.

To learn more, visit https://rejuvenatebio.com/
Linkedin: https://www.linkedin.com/company/rejuvenate-bio/

Contact:
Daniel Oliver, Chief Executive Officer
https://www.linkedin.com/in/danielcoliver/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.